DEVELCO Pharma GmbH is a 100% subsidiary of DEVELCO Pharma Schweiz AG based in Schopfheim and provides contract manufacturing services primarily for the parent company; revenue derives directly or indirectly from the parent’s orders. As a GMP‑certified pharmaceutical company it manufactures and packages generics for the German and European markets, with a focus on complex modified release forms (Modified Release Forms). The production site was established in 2016 to meet strict requirements for handling narcotics and in 2024 prepared insourcing transfers and portfolio expansions for methylphenidate and oxycodone products. In fiscal year 2024 the company achieved concrete performance increases: packaging output +16% (25 million blisters) and manufacturing output +98% (343 million tablets/capsules), accompanied by quality control, successful GMP audits and establishment of an HSE system.
Die Erbringung von Dienstleistungen für die pharmazeutische Industrie im Auftrag der Schweizer Muttergesellschaft der Develco Pharma Schweiz AG.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Freiburg Local Court, HRB 700223 (as of 31 October 2026)
| Name | Type | City |
|---|---|---|
| Annette Steiner-Kienzler | Geschäftsführer(in) | Erbach |
Source: German Commercial Register (Handelsregister) Freiburg Local Court, HRB 700223 (as of 31 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2024 | Rohergebnis€21.4M2 | €851,489 | €33,542,116 | 143 |
| 2023 | Rohergebnis€18.2M2 | €715,274 | €32,329,683 | 112 |
| 2022 | Rohergebnis€14M2 | €559,789 | €29,070,277 | 93 |
| 2021 | Rohergebnis€12.4M2 | €639,435 | €28,391,329 | 88 |
| 2020 | Rohergebnis€11.4M2 | €427,978 | €32,281,490 | 87 |
| 2019 | Rohergebnis€17.8M2 | €7,259,708 | €30,243,397 | 75 |
| 2018 | Rohergebnis€7.3M2 | €0 | €36,214,219 | 56 |
| 2017 | ≤ €12M1 | -€3,741,485 | €34,641,797 | 35 |
| 2016 | ≤ €12M1 | -€1,338,900 | €26,925,640 | 36 |
| 2015 | ≤ €12M1 | -€8,602 | €10,279,791 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Freiburg Local Court, HRB 700223 (as of 31 October 2026)
Amcor Flexibles Distribution Deutschland GmbH
Rheinbach · Herstellung von Verpackungsmitteln aus Kunststoffen
Dressler Group GmbH
Meckenheim · Herstellung von Maschinen für die Nahrungs- und Genussmittelerzeugung und die Tabakverarbeitung
Frankenberg Service GmbH
Würselen · Abfüllen und Verpacken
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €11,054,786 | 76.7% |
| Depreciation | €2,615,515 | 18.2% |
| Interest & Similar | €736,030 | 5.1% |
